Biomarkers predict benefit of adjuvant nivolumab in resected melanoma
Source: Helio, June 2023
Key takeaways:
- Four biomarkers appeared associated with longer RFS with nivolumab but not placebo.
- More research will examine the effect of additional biomarkers, as well as biomarker combinations.
CHICAGO — Several biomarkers predicted outcomes with adjuvant nivolumab vs. placebo for patients with resected stage IIB or IIC melanoma, according to study results presented at ASCO Annual Meeting.
In contrast to prior findings in melanoma, no biomarkers appeared prognostic for RFS among patients who received placebo.